West Pharmaceutical Services (WST) Receivables - Other (2017 - 2026)

West Pharmaceutical Services has disclosed Receivables - Other across 10 years of filings, most recently posting $15.4 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $15.4 million, down 40.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.4 million (down 40.31% YoY), and the FY2025 annual result was $11.9 million, down 48.93% from the prior year.
• Receivables - Other came in at $15.4 million for Q1 2026 at West Pharmaceutical Services, up from $11.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $42.3 million in Q3 2024 to a low of $11.9 million in Q4 2025.
• The 5-year median for Receivables - Other is $19.9 million (2023), against an average of $21.4 million.
• Across the five-year window, Receivables - Other jumped 112.56% in 2024 and sank 48.93% in 2025, its largest moves.
• West Pharmaceutical Services' Receivables - Other stood at $16.3 million in 2022, then jumped by 31.9% to $21.5 million in 2023, then gained by 8.37% to $23.3 million in 2024, then tumbled by 48.93% to $11.9 million in 2025, then advanced by 29.41% to $15.4 million in 2026.
• The last three Receivables - Other figures came in at $15.4 million (Q1 2026), $11.9 million (Q4 2025), and $27.5 million (Q3 2025), per Business Quant data.